NCT07069725View on ClinicalTrials.gov

The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 26, 2025

Primary Completion Date

February 19, 2026

Study Completion Date

February 19, 2026

Conditions
Liver FibrosisHepatic Cirrhosis
Interventions
DRUG

AZD2389

Doses of AZD2389 will be administrated orally

DIAGNOSTIC_TEST

PET scan and radioligand

PET scan and radioligand

Trial Locations (2)

17176

RECRUITING

Research Site, Stockholm

171 64

RECRUITING

Research Site, Solna

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

CTC Clinical Trial Consultants AB

INDUSTRY

collaborator

Karolinska Institutet

OTHER

lead

AstraZeneca

INDUSTRY